AGLE - Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
- Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80%.
- BLA filing of pegzilarginase for patients with ARG1-D is expected to occur in 1st half of 2022.
- Additional results from the phase 3 PEACE study, using pegzilarginase for patients with ARG1-D, are expected to be released at an upcoming medical meeting and in peer-reviewed medical journals.
- The company will also submit a regulatory application for pegzilarginase for ARG1-D, with its partner Immedica Pharma, to Europe and other Middle East countries in 2022.
For further details see:
Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower